Artiva Biotherapeutics Prices $300M Public Offering, Securing Funds for Phase 3 Clinical Development

summarizeSummary

Artiva Biotherapeutics priced a $300 million underwritten public offering of common stock and pre-funded warrants, generating approximately $280.5 million in net proceeds to fund the clinical development of its pipeline, including the AlloNK Phase 3 trial, following recent positive clinical data.

check_boxKey Events

• Prices $300 Million Public Offering

  Artiva Biotherapeutics priced an underwritten public offering of 23,871,526 shares of common stock and pre-funded warrants to purchase up to 2,170,138 shares. The offering price for common stock was $11.52 per share, and $11.5199 per pre-funded warrant, representing a discount to the prior day's closing price of $12.52.

• Secures $280.5 Million in Net Proceeds

  The company expects to receive net proceeds of approximately $280.5 million after deducting underwriting discounts and estimated offering expenses. These proceeds are earmarked for funding clinical development of pipeline candidates, manufacturing, and general corporate purposes.

• Significant Potential Dilution

  The offering could result in substantial dilution, with the total number of shares and warrants offered (26,041,664) representing over 100% of the currently outstanding shares (24,716,672 as of March 31, 2026).

• Strategic Timing Post-Positive Clinical Data

  This capital raise follows the announcement of positive initial clinical data for AlloNK in autoimmune diseases and FDA alignment for a Phase 3 trial, providing critical funding to advance the lead program.

auto_awesomeAnalysis

Artiva Biotherapeutics has finalized a substantial public offering, raising approximately $280.5 million in net proceeds. This capital raise, which is greater than the company's current market capitalization and could result in over 100% dilution if all shares and warrants are issued, is strategically timed following positive initial clinical data for its lead program, AlloNK, and FDA alignment for a Phase 3 trial. While highly dilutive for existing shareholders, the significant funding is critical for advancing AlloNK's clinical development, including the planned Phase 3 registrational trial in refractory rheumatoid arthritis, and provides a crucial runway for the company's operations. The offering was priced at a discount to the previous day's close but at a premium to the current market price, indicating institutional demand despite the dilutive impact. This move replaces a smaller, existing ATM facility, signaling a more decisive and larger-scale financing strategy.